We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.
Medicine

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

What Factors Contribute to Trastuzumab Resistance?

Mary McMahon
By
Updated: May 17, 2024

Resistance to trastuzumab, a cancer medication, can occur for a variety of genetic and environmental reasons. This drug targets a specific receptor known as HER2 found in some breast cancer cases. It inhibits cell growth, halting further development of the cancer, and can be used in combination with surgery, radiation, and other chemotherapy drugs. Treatment with trastuzumab can improve outcomes for breast cancer patients, especially when it is used in combination therapy, but some tend to develop resistance to the drug when used over a period of time.

In some cases, a patient successfully treated with trastuzumab initially develops a recurrence, in which case the new tumor is likely resistant to the drug. Other patients may experience initial success on trastuzumab, only to find that the tumor starts growing again and shows signs of resistance. Some may experience poor outcomes on trastuzumab therapy from the start. The reasons for this are complex, and involve changes to molecular signaling pathways involved in cancer growth.

Like other cells in the body, cancer cells adapt to their circumstances. In treatment with trastuzumab, the tumor learns that it cannot keep growing, and it develops workarounds. It can send signals to increase the expression of some molecular compounds, or to suppress others. If it can successfully change the patient's signaling pathways, it can start growing again. Some of the compounds involved in trastuzumab resistance include glycoproteins, tyrosine kinases, and microRNA.

The genetics of each patient are slightly different and can contribute to trastuzumab resistance in various ways. In patients with HER2 sensitive breast cancers, some may have a genetic predisposition for trastuzumab resistance. These patients will develop signs of resistance earlier than others, and may not experience positive outcomes with their cancer therapy. Others may have more forgiving genetics, and their cancers take longer to figure out how to short-circuit the medication and keep growing. It can be hard to predict which patients will respond best.

Management of trastuzumab resistance can take a number of approaches. One option is combination therapy to keep the tumor under attack so it cannot develop resistance as quickly. It is also possible to administer medications to block some of the signaling pathway changes. For example, if the tumor directs the body to produce more of a given compound, a drug can block production, thwarting the tumor's attempt to develop trastuzumab resistance. Research on cancer therapy includes exploration of a number of options for treating medication-resistant cancers and improving patient outcomes.

WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Mary McMahon
By Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a WiseGeek researcher and writer. Mary has a liberal arts degree from Goddard College and spends her free time reading, cooking, and exploring the great outdoors.

Discussion Comments
Mary McMahon
Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a...

Learn more
Share
https://www.wisegeek.net/what-factors-contribute-to-trastuzumab-resistance.htm
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.